Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting

Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting

Oslo, Norway, 9 March 2022

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces that an E-poster regarding Alpha37, entitled “Targeted alpha therapy with ²¹²Pb-NNV003 in treatment of NHL”, will be presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting held 8-13 April in New Orleans, USA.

The data in the E-poster show that a single injection of ²¹²Pb-NNV003, or Alpha37, is safe and effective for the treatment of CD37-positive chronic lymphocytic leukaemia (CLL) and non-Hodgkin’s lymphoma (NHL) in mouse models. Promising efficacy in both ibrutinib-resistant and ibrutinib-sensitive CLL models was observed and treatment with Alpha37 was superior to both ibrutinib and oblinutuzumab, confirming that further clinical development is warranted. These data were previously presented at the company’s R&D Day in November 2021.

Alpha37 has been developed as a targeted alpha radioimmunotherapy where the CD37-specific antibody NNV003 is coupled to the alpha particle generating isotope ²¹²Pb for the treatment of NHL and CLL. Despite the availability of current treatments, most patients with these diseases inevitably relapse meaning that there is a significant unmet need for new, alternative therapies.

Jostein Dahle, Co-founder and CSO of Nordic Nanovector, commented: “The pre-clinical data that we have amassed on Alpha37 is taking us closer towards our goal of filing for an IND to begin human clinical testing. We are focussed on high risk and/or ibrutinib resistant/refractory CLL as the entry indication but believe there is a broader unmet need beyond this that Alpha37 may be able to fulfil.  We look forward to the further development of this next generation targeted anti-CD37 alpha radio-immunoconjugate.”

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com